RNA Insider Steven George Executes 10b5-1 Plan: 2,208 Shares Exercised and Sold
Rhea-AI Filing Summary
Avidity Biosciences insider Steven George, the company's Chief Medical Officer, reported option exercises and a contemporaneous sale on 09/22/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised a stock option with a $10.16 exercise price for 2,208 shares, increasing his underlying option holdings by 2,208 shares exercisable through 01/19/2034 and resulting in total beneficial ownership of 70,667 shares. Simultaneously, 2,208 common shares were sold at $40.58, leaving him with 41,075 shares owned directly after the transactions. The filing states the 10b5-1 plan was adopted on 06/12/2024 and the option grant date was 01/20/2024.
Positive
- Transactions executed under a Rule 10b5-1 plan, indicating pre-planned trades and increased transparency.
- Clear disclosure of option grant, vesting schedule, and resulting beneficial ownership, aiding investor understanding.
Negative
- Insider sold 2,208 shares at $40.58, reducing direct holdings to 41,075 shares.
- Exercise and sale indicate insider liquidity, which some investors may interpret unfavorably despite 10b5-1 protections.
Insights
TL;DR: Insider exercised and sold equal shares under a 10b5-1 plan; routine liquidity action with limited immediate valuation signal.
The reporting shows a coordinated exercise and sale of 2,208 shares at an exercise price of $10.16 and a sale price of $40.58, executed under a 10b5-1 plan adopted 06/12/2024. Such transactions commonly reflect planned liquidity rather than ad-hoc insider trading. The resultant direct beneficial ownership figures—41,075 shares held after sale and 70,667 shares beneficially owned including unexercised options—are clearly disclosed, supporting transparency for market participants.
TL;DR: Use of a documented 10b5-1 plan and clear disclosure aligns with governance best practices.
The Form 4 indicates the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted 06/12/2024 and were signed by an attorney-in-fact on 09/23/2025. The filing includes the grant and vesting terms for the option (grant date 01/20/2024; monthly vesting through 01/20/2028), which enhances clarity about the insider's equity incentives and timing. From a governance standpoint, documented pre-arranged trades reduce concerns about opportunistic timing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,208 | $0.00 | -- |
| Exercise | Common Stock | 2,208 | $10.16 | $22K |
| Sale | Common Stock | 2,208 | $40.58 | $90K |
Footnotes (1)
- The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.
